Good Company

Loyal Is Building the First Longevity Drug Category for Dogs

The San Francisco biotech has raised more than $250 million, cleared two of three FDA sections for its lead senior dog pill, and in September added a third efficacy acceptance, all before selling a single dose.

By Good Company Editorial Desk

Loyal logo

The News

Every pet drug on the market today treats something that has already gone wrong: an infection, a painful joint, a failing heart. Loyal is building drugs for a different target altogether. The San Francisco company wants the Food and Drug Administration to approve medicines whose stated purpose is to extend a dog's lifespan itself, and to keep that dog healthier while it lives longer. No drug, for any species, has ever been approved for that purpose. Loyal, founded in late 2019 by Celine Halioua, is now closer to that line than anyone else has been.

The clearest sign came in February 2026. Loyal raised a $100 million Series C led by age1, the next generation of Laura Deming's Longevity Fund, with participation from Baillie Gifford and existing investors. The company says the round brought total investment in Loyal to more than $250 million since its founding. That is launch money, not science project money. Loyal said it would use the capital to complete the remaining FDA requirements for its lead program, scale its team, build distribution channels and prepare for a commercial launch.

The lead program is LOY-002, a prescription daily pill for senior dogs. The company says it is intended for dogs age 10 or older weighing at least 14 pounds, and that it works by targeting the metabolic drivers of aging, including the metabolic dysfunction that develops as dogs get older. Fast Company described the approach as mimicking some of the effects of a calorie restricted diet, without asking owners to feed their dogs less. The company has not disclosed the drug's active ingredient, saying the exact mechanisms for its programs remain confidential before approval.

LOY-002 has cleared two of the three major technical sections the FDA's Center for Veterinary Medicine requires for Expanded Conditional Approval, known as XCA. The agency accepted the Reasonable Expectation of Effectiveness section, called RXE, in February 2025. It accepted the Target Animal Safety section, called TAS, in January 2026. The safety package included a standard safety study and field safety data from more than 400 dogs in the company's pivotal trial, according to Loyal. Only one major section remains: the manufacturing section, covering whether the drug can be made consistently at scale. In February the company said that final requirement was in progress and that it planned to submit it for review later this year. As of November 2026 the company still lists two of three requirements complete, and it states plainly that FDA approval is not guaranteed.

Behind that filing sits the STAY study, LOY-002's pivotal effectiveness trial. Loyal says STAY is a double blinded, placebo controlled study that finished enrolling in July 2025, with about 1,300 dogs at 70 veterinary clinics nationwide. The company calls it the largest clinical trial in the history of veterinary medicine. The study dosed its first dog in December 2023 and runs for about four years, which means the lifespan question at the heart of the company will not be fully answered by STAY until well after a conditional approval decision. No STAY lifespan results have been released.

LOY-002 is not the whole company. Two more programs aim at a well known unfairness in dog biology: large and giant breeds age faster and die years earlier than small dogs. Loyal's explanation is growth hormone and insulin like growth factor 1, or IGF-1. Selective breeding for size left large dogs with far higher IGF-1 levels, and the company believes that overexpression helps drive their shorter lives. LOY-001, a long acting injection given by a veterinarian every three to six months, received RXE acceptance in November 2023. Loyal described that as the first RXE acceptance for a lifespan extension drug in any species. LOY-003, a daily pill aimed at the same large dog population and the same growth hormone and IGF-1 pathway, received its RXE acceptance on September 16, 2026. With that news, all three drugs in the portfolio had completed the efficacy requirement for conditional approval, a first for any company, according to Loyal. LOY-001 and LOY-003 still need their safety and manufacturing sections, and Loyal's own veterinarian materials project conditional approval for the large dog programs in 2027.

Halioua's path to this point explains some of the investor patience. Before founding Loyal at 24, she was chief of staff to Laura Deming at The Longevity Fund, one of the first venture funds built around aging science, and she left a doctoral program at Oxford to start the company. The early backing followed that lineage: an $11 million seed, then a $27 million Series A in 2021 led by Khosla Ventures, with First Round Capital and others, on the way to more than $250 million in total.

"Our driving purpose at Loyal is to help dogs live longer, healthier lives," Halioua said in the February Series C announcement. "We're closer than ever to delivering a solution to the problem we set out to solve: an FDA-approved drug for canine lifespan extension. This capital will help our team see our lead program through the remaining FDA requirements and get to market."

Why It Matters

Conditional approval is the hinge, and it is worth being precise about what it does and does not mean. The XCA pathway, opened by the FDA in 2019 for innovative drugs that fill unmet needs, lets a company market a drug once it has shown safety, manufacturing quality and a reasonable expectation of effectiveness, while the full proof of effectiveness is still being collected. That last phrase is a lower bar than the substantial evidence a full approval requires. RXE acceptance means the agency found Loyal's early data and reasoning credible enough to expect the drug works. It does not mean the drug has been shown to add years to a dog's life, and Loyal's own materials say approval is not guaranteed.

Even with that caveat, Loyal has already changed the regulatory map. Before Loyal, lifespan was not really a label a drug company could chase. Regulators approved drugs for named diseases and conditions. By winning the first RXE acceptances for lifespan extension, first for large dogs in 2023, then for senior dogs in 2025, then for a third program in 2026, Loyal persuaded the FDA to treat aging biology itself as a developable target in dogs. That precedent belongs to Loyal now, whatever happens to any single program, and every follower will build on the path it negotiated.

The commercial logic is just as deliberate. A lifespan drug is preventive and chronic. It is given to a healthy or aging dog, every day or a few times a year, potentially for years, through a veterinarian, to an owner who has already shown the industry how much they will spend to keep a dog well for longer. That is a very different business from a course of treatment for an acute problem. It looks more like the preventive franchises that anchor animal health economics today, except the promise is bigger and the evidence bar is new territory for everyone involved, regulator included.

There is also a second audience for this work that Loyal has never hidden. Dogs age in years, not decades, they share homes and environments with people, and a lifespan trial that would take a lifetime in humans can read out in a dog study in a few years. Success in dogs would not prove anything about a human drug, and Loyal is a veterinary company, not a human longevity company in disguise. But the regulatory and scientific template, how you design a trial for lifespan, what endpoints a regulator accepts, how you talk about healthspan honestly, is being written here first, in veterinary medicine, in public.

The Numbers

  • Founded: late 2019 in San Francisco, California, by founder and CEO Celine Halioua
  • Total raised: more than $250 million since founding, according to the company (February 2026)
  • Latest round: $100 million Series C, announced February 11, 2026, led by age1 with participation from Baillie Gifford and existing investors
  • Earlier rounds the company has announced include an $11 million seed and a $27 million Series A in 2021 led by Khosla Ventures
  • Share of the year: the $100 million Series C was 51.6 percent of all disclosed pet tech and pet health venture dollars tracked from January through October 2026, about $194 million across 16 disclosed rounds out of 20 tracked (The Underbite)
  • Programs: 3 drugs in development, LOY-001, LOY-002 and LOY-003
  • LOY-002: daily flavored prescription pill, dogs age 10 or older and at least 14 pounds, targeting metabolic drivers of aging
  • LOY-002 regulatory status at November 2026: RXE accepted February 2025, Target Animal Safety accepted January 2026, manufacturing section in progress; 2 of 3 major XCA requirements complete, approval not guaranteed
  • STAY study: about 1,300 dogs, 70 veterinary clinics nationwide, enrollment completed July 2025, double blinded and placebo controlled, about four years in duration, no lifespan results released yet
  • Safety package: standard safety study plus field safety data from more than 400 dogs on LOY-002 in STAY, according to the company
  • LOY-001: long acting prescription injection for large and giant dogs, RXE accepted November 2023, the first such acceptance for lifespan extension in any species, according to the company
  • LOY-003: daily pill for large and giant dogs targeting growth hormone and IGF-1, RXE accepted September 16, 2026; all three portfolio programs have now completed the XCA efficacy requirement
  • Price, launch date and final label: not announced. The company said in February it planned to submit the final LOY-002 requirement for review later in 2026

What It Means For You

If you run a veterinary clinic, start thinking about the conversation now, before any product exists to sell. A preventive lifespan drug will arrive, if it arrives, with a conditional label, an unfinished pivotal trial and owners who have read headlines that say a pill adds years to a dog's life. Your team will be the ones explaining the difference between a reasonable expectation of effectiveness and proven lifespan extension, in an exam room, to someone who loves an old dog. Clinics that prepare an honest, calm version of that conversation early will own the trust in this category. Clinics that oversell it will own the disappointment.

If you sell pet health products of any kind, notice what a lifespan category does to the shelf and the calendar. A daily drug for senior dogs competes for the same owner budget and the same daily routine as supplements, therapeutic diets, joint products and wellness plans. It also moves the senior conversation earlier and makes it medical. Brands that today own the senior life stage with food, supplements and monitoring will need a point of view on longevity medicine, even if that point of view is simply how their product fits alongside a prescription drug. Silence will read as absence.

If you are building or funding in pet health, Loyal is the proof that the FDA's conditional pathway can support a genuinely new category, and also a warning about the cost of going first. More than $250 million and seven years in, the company has no product revenue from its lead drug yet, and its most important trial reads out years from now. The followers are already visible: startups licensing human drugs for pets and building personalized cancer vaccines for dogs are working the same regulatory territory Loyal opened. The advantage of the pioneer is the precedent and the brand. The burden is paying to create both.

And if you compete with Loyal directly or sit at one of the large animal health incumbents, the thing to notice is not a launch date. It is that a startup, not an incumbent, defined this category, enrolled the largest trial in veterinary history to support it, and raised longevity fund and institutional money to finish the job. Whether LOY-002 succeeds or stalls at manufacturing review, preventive aging is now a line item in the industry's future that has to be answered in product planning, not just watched in the press.

What To Watch

Watch the manufacturing section. It is the only gate left between Loyal and a conditional approval application for LOY-002, and it is the least glamorous and most unforgiving part of drug development. The company said in February it planned to submit it later this year. A submission, an acceptance, or a quiet slip in that language in the company's next updates will tell you more about the real timeline than any launch speculation.

Watch how the company talks about timing from here. In January, Loyal said it expected to complete the final section and apply for conditional approval next year. In February, it said the final requirement submission was planned for later this year. Those statements can both be true, submission in 2026 and an application and review running into 2027, but the gap between them is exactly where expectations will be set or missed. Hold every timeline as a company statement, not a promise, until the FDA acts.

Watch STAY, even though it will not read out soon. Enrollment is done, the dogs are aging on study, and the trial's eventual result is the difference between a conditional product with a good story and a proven lifespan drug with a defensible label. Any interim safety or healthspan disclosures from the study deserve close reading, and so does the absence of them.

Watch the large dog programs. LOY-003's September efficacy acceptance means the second wave is real, and Loyal projects the large dog drugs could reach conditional approval in 2027. A portfolio matters here: if the senior dog pill establishes the channel, the veterinarian relationships and the owner habit, LOY-001 and LOY-003 arrive into a market Loyal has already taught how to buy longevity.

Finally, watch who follows. New pet drug startups are forming around repurposed human medicines and individualized cancer treatments, and incumbents have shown this year that they will buy novel pet therapies rather than only build them. If lifespan becomes a category, it will not stay a one company category for long. Loyal's job is to be approved, trusted and already in the exam room when the second entrant arrives.

Sources

  • Loyal, "Loyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity Drug," Business Wire, February 11, 2026: https://www.businesswire.com/news/home/20260211301175/en/Loyal-Raises-%24100M-Series-C-Led-by-age1-to-Advance-the-First-Canine-Longevity-Drug
  • Loyal, "Loyal Receives FDA Acceptance of Safety Package for Senior Dog Lifespan Extension Drug," Business Wire, January 13, 2026: https://www.businesswire.com/news/home/20260113476778/en/Loyal-Receives-FDA-Acceptance-of-Safety-Package-for-Senior-Dog-Lifespan-Extension-Drug
  • Loyal, "Loyal Receives FDA Acceptance of Reasonable Expectation of Effectiveness for Senior Dog Lifespan Extension," Business Wire, February 26, 2025: https://www.businesswire.com/news/home/20250226676005/en
  • Loyal, "Loyal Earns Third Efficacy Acceptance (RXE) from the FDA for Canine Lifespan Extension" (LOY-003), Business Wire, September 16, 2026
  • Loyal, "FDA Agrees Loyal Data Supports Reasonable Expectation of Effectiveness for Large Dog Lifespan Extension" (LOY-001), Business Wire, November 28, 2023: https://www.businesswire.com/news/home/20231127326868/en/FDA-Agrees-Loyal-Data-Supports-Reasonable-Expectation-of-Effectiveness-for-Large-Dog-Lifespan-Extension
  • Loyal, product brief for veterinarians, loyal.com: https://Loyal.com/downloads/Loyal-product-brief-for-vets-v7.pdf
  • Fast Company, "This startup raised $250 million to help dogs live longer," February 11, 2026: https://www.fastcompany.com/91490365/loyal-startup-250-million-help-dogs-live-longer
  • The Underbite, "Pet Tech Funding 2026: Where the Money Actually Went": https://www.theunderbite.co/technology/pet-tech-landscape
  • Stanford Entrepreneurial Thought Leaders, Celine Halioua speaker biography: https://events.stanford.edu/event/celine-halioua-entrepreneurial-thought-leaders-speaker-series-etl